Items Tagged ‘tyrosine kinase inhibitor’

December 14th, 2016

FDA Grants Iclusig® Expanded Approval for CML

By

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, CML, Iclusig, Leukemia, News, PACE trial, Ph+ ALL, ponatinib, TKI, tyrosine kinase inhibitor